Treatment of metastatic colorectal cancer by means of specific monoclonal antibodies conjugated with iodine-131: a phase II study

Riva, P.; Marangolo, M.; Tison, V.; Armaroli, L.; Moscatelli, G; Franceschi, G.; Spinelli, A.; Vecchietti, G; Morigi, P; Tassini, R.; Riva, Nb.; Tirindelli, Donatella

doi:10.1016/0883-2897(91)90057-r

Cited by 10 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The feasibility and clinical efficacy of conjugated mAbs for treatment of CRC was demonstrated decades ago in a 1991 study of mCRC patients treated with either a CEA- or tumor-associated glycoprotein (TAG)-targeting mAb conjugated to iodine-13 [ 111 ]. Since then, several other studies have demonstrated that conjugated mAbs can be efficacious for treatment of CRC.…”

Section: Colorectal Cancer Response To Immunotherapymentioning

confidence: 99%

Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers

Carlsen

Huntington

El‐Deiry

2022

Cancers

View full text Add to dashboard Cite

Though early-stage colorectal cancer has a high 5 year survival rate of 65–92% depending on the specific stage, this probability drops to 13% after the cancer metastasizes. Frontline treatments for colorectal cancer such as chemotherapy and radiation often produce dose-limiting toxicities in patients and acquired resistance in cancer cells. Additional targeted treatments are needed to improve patient outcomes and quality of life. Immunotherapy involves treatment with peptides, cells, antibodies, viruses, or small molecules to engage or train the immune system to kill cancer cells. Preclinical and clinical investigations of immunotherapy for treatment of colorectal cancer including immune checkpoint blockade, adoptive cell therapy, monoclonal antibodies, oncolytic viruses, anti-cancer vaccines, and immune system modulators have been promising, but demonstrate limitations for patients with proficient mismatch repair enzymes. In this review, we discuss preclinical and clinical studies investigating immunotherapy for treatment of colorectal cancer and predictive biomarkers for response to these treatments. We also consider open questions including optimal combination treatments to maximize efficacy, minimize toxicity, and prevent acquired resistance and approaches to sensitize mismatch repair-proficient patients to immunotherapy.

show abstract

Section: Colorectal Cancer Response To Immunotherapymentioning

confidence: 99%

Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers

Carlsen

Huntington

El‐Deiry

2022

Cancers

View full text Add to dashboard Cite

show abstract

“…The feasibility and clinical efficacy of conjugated mAbs for treatment of CRC was demonstrated decades ago in a 1991 study of mCRC patients treated with either a CEA-or tumor associated glycoprotein (TAG)-targeting mAb conjugated to iodine-13 [69]. Since then, several other studies have demonstrated that conjugated mAbs can be efficacious for treatment of CRC.…”

Section: Conjugated Monoclonal Antibodiesmentioning

confidence: 99%

Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers

Carlsen¹,

Huntington²,

El‐Deiry³

2021

Preprint

View full text Add to dashboard Cite

Though early-stage colorectal cancer has a high 5-year survival rate of 65-92% depending on the specific stage, this probability drops to 13% after the cancer metastasizes. Frontline treatments for colorectal cancer such as chemotherapy and radiation often produce dose-limiting toxicities in patients and acquired resistance in cancer cells. Additional targeted treatments are needed to improve patient outcomes and quality of life. Immunotherapy involves treatment with peptides, cells, antibodies, viruses, or small molecules to engage or train the immune system to kill cancer cells. Preclinical and clinical investigations of immunotherapy for treatment of colorectal cancer including immune checkpoint blockade, adoptive cell therapy, monoclonal antibodies, oncolytic viruses, anti-cancer vaccines, and immune system modulators have been promising, but demonstrate limitations for patients with proficient mismatch repair enzymes. In this review, we discuss preclinical and clinical studies investigating immunotherapy for treatment of colorectal cancer and predictive biomarkers for response to these treatments. We also consider open questions including optimal combination treatments to maximize efficacy, minimize toxicity, and prevent acquired resistance and approaches to sensitize mismatch repair proficient patients to immunotherapy.

show abstract